A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic Therapy—Problems, Solutions, and Prospects

Microcirculation

Volumn 23, Issue 3, 2016, Pages 173-182

  Maeda, Hiroshi ^a   Tsukigawa, Kenji ^a   Fang, Jun ^a  

^a SOJO UNIVERSITY   (Japan)

Author keywords

anticancer therapy; enhanced permeability and retention effect; nanomedicine; photodynamic therapy

Indexed keywords

DOXORUBICIN; ENALAPRIL; LIPOSOME; NANOPARTICLE; PHOTOFRIN; PIRARUBICIN; POLYMER; TALAPORFIN; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; DRUG DELIVERY SYSTEM; ENHANCED PERMEABILITY AND RETENTION EFFECT; HISTORY OF MEDICINE; HUMAN; METASTASIS; MICELLE; NANOENCAPSULATION; NANOMEDICINE; NONHUMAN; ONCOLOGICAL PARAMETERS; PHOTODYNAMIC THERAPY; REVIEW; SOLID TUMOR; TROPISM; TUMOR CELL; TUMOR MICROENVIRONMENT; BLOOD; HISTORY; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PERMEABILITY; PHOTOCHEMOTHERAPY; PROCEDURES;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PERMEABILITY; PHOTOCHEMOTHERAPY;

EID: 85011344703     PISSN: 10739688     EISSN: 15498719     Source Type: Journal    
DOI: 10.1111/micc.12228     Document Type: Review

References (82)

1. Alvarez JV, Belka GK, Pan TC, Chen CC, Blankemeyer E, Alavi A, Karp JS, Chodosh LA. Oncogene pathway activation in mammary tumors dictates FDG-PET uptake. Cancer Res 74: 7583–7598, 2014.
2. Chouikrat R, Seve A, Vanderesse R, Benachour H, Barberi-Heyob M, Richeter S, Raehm L, Durand JO, Verelst M, Frochot C. Non-polymeric nanoparticles for photodynamic therapy applications: recent developments. Curr Med Chem 19: 781–792, 2012.
3. Chytil P, Hoffmann S, Schindler L, Kostka L, Ulbrich K, Caysa H, Mueller T, Mäder K, Etrych T. Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release II: impact of release rate on biodistribution. J Control Release 172: 504–512, 2013.
4. Daruwalla J, Greish K, Nikfarjam M, Millar I, Malcontenti-Wilson C, Iyer AK, Christophi C. Evaluation of the effect of SMA-pirarubicin micelles on colorectal cancer liver metastases and of hyperbaric oxygen in CBA mice. J Drug Target 15: 487–495, 2007.
5. Daruwalla J, Greish K, Wilson CM, Muralidharan V, Iyer A, Maeda H, Christophi C. Styrene maleic acid-pirarubicin disrupts tumor microcirculation and enhances the permeability of colorectal liver metastases. J Vasc Res 46: 218–228, 2009.
6. Daruwalla J, Nikfarjam M, Greish K, Malcontenti-WilsonI C, Muralidharan V, Christophi C, Maeda H. In vitro and in vivo evaluation of tumor targeting styrene-maleic acid copolymer-pirarubicin micelles: survival improvement and inhibition of liver metastases. Cancer Sci 101: 1866–1874, 2010.
7. Dozono H, Yanazume S, Nakamura H, Etrych T, Chytil P, Ulbrich K, Fang J, Arimura T, Douchi T, Kobayashi H, Ikoma M, Maeda H. HPMA polymer-conjugated pirarubicin in multimodal treatment of a patient with stage IV prostate cancer and extensive lung and bone metastases. Target Oncol doi: 10.1007/s11523-015-0379-4, 2015.
8. Duncan R. Polymer-drug conjugates: targeting cancer. In: Biomedical Aspects of Drug Targeting, edited by Muzykantov VR, Torchilin VP. Norwell, MA: Kluwer Academic Publishers, 2002, p. 193–209.
9. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 8: 2101–2141, 2011.
10. Fang J, Liao L, Yin H, Nakamura H, Shin T, Maeda H. Enhanced bacterial tumor delivery by modulating the EPR effect, and therapeutic potential of Lactobacillus casei. J Pharm Sci 103: 3235–3243, 2014.
11. Fang J, Liao L, Yin H, Nakamura H, Subr V, Ulbrich K, Maeda H. Photodynamic therapy based on tumor-targeted polymer-conjugated zinc protoporphyrin and irradiation with xenon light [Online]. Future Science OA, FSO4. http://www.future-science.com/doi/pdf/10.4155/fso.15.2. [2015]
12. Fang J, Qin H, Nakamura H, Tsukigawa K, Maeda H. Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention (EPR) effect of solid tumor. Cancer Sci 102: 535–541, 2012.
13. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892, 2012.
14. Gormley AJ, Larson N, Sadekar S, Robinson R, Ray A, Ghandehari H. Guided delivery of polymer therapeutics using plasmonic photothermal therapy. Nano Today 7: 158–167, 2012.
15. Greish K, Nagamitsu A, Fang J, Maeda H. Copoly (styrene-maleic-acid)-pirarubicin micelles: high tumor targeting efficacy with low toxicity. Bioconj Chem 16: 230–236, 2005.
16. Greish K, Sawa T, Fang J, Akaike T, Maeda H. SMA-doxorubicin, a new polymeric micellar drug for effective anticancer targeting. J Control Release 97: 219–230, 2004.
17. Hare JI, Moase EH, Allen TM. Targeting combinations of liposomal drugs to both tumor vasculature cells and tumor cells for the treatment of HER2-positive breast cancer. J Drug Target 21: 87–96, 2013.
18. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, Stewart JS. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7: 243–254, 2001.
19. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156: 1363–1380, 2000.
20. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 14: 4607–4612, 1998.
21. Hollis CP, Weiss HL, Leggas M, Evers BM, Gemeinhart RA, Li T. Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. J Control Release 172: 12–21, 2013.
22. Hori K, Suzuki M, Tanda S, Saito S, Zhang Q. Functional-characterization of developing tumor vascular system and drug delivery (review). Int J Oncol 2: 289–296, 1993.
23. Iwai K, Maeda H, Konno T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res 44: 2115–2121, 1984.
24. Iyer AK, Greish K, Seki T, Okazaki S, Fang J, Takeshita K, Maeda H. Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation. J Drug Target 15: 496–506, 2007.
25. Janssens MY, Van den Berge DL, Verovski VN, Monsaert C, Storme GA. Activation of inducible nitric oxide synthase results in nitric oxide-mediated radiosensitization of hypoxic EMT-6 tumor cells. Cancer Res 58: 5646–5648, 1998.
26. Kano MR, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M, Fujii T, Komuro A, Kiyono K, Kaminishi M, Hirakawa K, Ouchi Y, Nishiyama N, Kataoka K, Miyazono K. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc Natl Acad Sci USA 104: 3460–3465, 2007.
27. Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug Chem 22: 1879–1903, 2011.
28. Konno T, Maeda H, Iwai K, Maki S, Tashiro S, Uchida M, Miyauchi Y. Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 54: 2367–2374, 1984.
29. Konno T, Maeda H, Iwai K, Tashiro S, Maki S, Morinaga T, Mochinaga M, Hiraoka T, Yokoyama I. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 19: 1053–1065, 1983.
30. Koshi H, Sano T, Handa T, Yanagawa T, Saitou K, Nagamori S, Kanai Y, Takagishi K, Oyama T. L-type amino acid transporter-1 and CD98 expression in bone and soft tissue tumors. Pathol Int (2015). doi:10.1111/pin.12323.
31. Kratz F, Beyer U, Schumacher P, Krüger M, Zahn H, Roth T, Fiebig HH, Unger C. Synthesis of new maleimide derivatives of daunorubicin and biological activity of acid labile transferrin conjugates. Bioorg Med Chem Lett 7: 617–622, 1997.
32. Kuo WS, Chang CN, Chang YT, Yeh CS. Antimicrobial gold nanorods with dual-modality photodynamic inactivation and hyperthermia. Chem Commun 28: 4853–4855, 2009.
33. Lammers T. Drug delivery research in Europe. J Control Release 161: 151, 2012.
34. Lammers T, Subr V, Ulbrich K, Hennink WE, Storm G, Kiessling F. Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy. Nano Today 5: 197–212, 2010.
35. Lim CK, Heo J, Shin S, Jeong K, Seo YH, Jang WD, Park CR, Park SY, Kim S, Kwon IC. Nanophotosensitizers toward advanced photodynamic therapy of cancer. Cancer Lett 334: 176–187, 2013.
36. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 6: 181–202, 1991.
37. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release 164: 138–144, 2012.
38. Maeda H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B 88: 53–71, 2012.
39. Maeda H. The link between infection and cancer: tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect. Cancer Sci 104: 779–789, 2013.
40. Maeda H. Emergence of EPR effect theory and development of clinical applications for cancer therapy. Ther Deliv 5: 627–630, 2014.
41. Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev doi: 10.1016/j.addr.2015.01.002, 2015.
42. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 71: 409–419, 2009.
43. Maeda H, Fang J, Inuzuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 3: 319–328, 2003.
44. Maeda H, Matsumoto T, Konno T, Iwai K, Ueda M. Tailor-making of protein drugs by polymer conjugation for tumor targeting: a brief review on SMANCS. J Protein Chem 3: 181–193, 1984.
45. Maeda H, Matsumura Y, Oda T, Sasamoto K. Cancer selective macromolecular therapeutics: tailoring of an antitumor protein drug. In: Protein Tailoring for Food and Medical Uses, edited by Feeney RE, Whitaker JR. New York; Basel: Marcel Dekker, 1986, p. 353–382.
46. Maeda H, Takeshita J, Kanamaru R. A lipophilic derivative of neocarzinostatin: a polymer conjugation of an antitumor protein antibiotic. Int J Pept Protein Res 14: 81–87, 1979.
47. Maeda H, Takeshita J, Yamashita A. Lymphotropic accumulation of an antitumor antibiotic protein, neocarzinostatin. Eur J Cancer 16: 723–731, 1980.
48. Maeda H, Ueda M, Morinaga T, Matsumoto T. Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties. J Med Chem 28: 455–461, 1985.
49. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 46: 6387–6392, 1986.
50. Minko T, Kopecková P, Pozharov V, Kopecek J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release 54: 223–233, 1998.
51. Miyamoto Y, Maeda H. Enhancement by verapamil of neocarzinostatin action on multidrug-resistant Chinese hamster ovary cells: possible release of nonprotein chromophore in cells. Jpn J Cancer Res 82: 351–356, 1991.
52. Miyamoto Y, Oda T, Maeda H. Comparison of the cytotoxic effects of the high- and low-molecular-weight anticancer agents on multidrug-resistant Chinese hamster ovary cells in vitro. Cancer Res 50: 1571–1575, 1990.
53. Nagamitsu A, Greish K, Maeda H. Elevating blood pressure as a strategy to increase tumor targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn J Clin Oncol 39: 756–766, 2009.
54. Nakamura H, Etrych T, Chytil P, Ohkubo M, Fang J, Ulbrich K, Maeda H. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. J Control Release 174: 81–87, 2014.
55. Nakamura H, Fang J, Maeda H. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls. Expert Opin Drug Deliv 12: 53–64, 2015.
56. Nakamura H, Koziolovác E, Etrych T, Chytil P, Fang J, Ulbrich K, Maeda H. Comparison between linear and star-like HPMA conjugated pirarubicin (THP) in pharmacokinetics and antitumor activity in tumor bearing mice. Eur J Pharm Biopharm 90: 90–96, 2015.
57. Nakamura H, Liao L, Hitaka Y, Tsukigawa K, Subr V, Fang J, Ulbrich K, Maeda H. Micelles of zinc protoporphyrin conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer for imaging and light-induced antitumor effects in vivo. J Control Release 165: 191–198, 2013.
58. Nakanishi T, Fukushima S, Okamoto K, Suzuki M, Matsumura Y, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Development of the polymer micelle carrier system for doxorubicin. J Control Release 74: 295–302, 2001.
59. Namikawa M, Kakizaki S, Kaira K, Tojima H, Yamazaki Y, Horiguchi N, Sato K, Oriuchi N, Tominaga H, Sunose Y, Nagamori S, Kanai Y, Oyama T, Takeyoshi I, Yamada M. Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma. Hepatol Res (2015) doi:10.1111/hepr.12431.
60. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, Maeda H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 89: 307–314, 1998.
61. Ohtsuka N, Konno T, Miyauchi Y, Maeda H. Anticancer effects of arterial administration of the anticancer agent SMANCS with Lipiodol on metastatic lymph nodes. Cancer 59: 1560–1565, 1987.
62. Owen SC, Doak AK, Wassam P, Shoichet MS, Shoichet BK. Colloidal aggregation affects the efficacy of anticancer drugs in cell culture. ACS Chem Biol 7: 1429–1435, 2012.
63. Prabhakar U, Maeda H, Jain RK, Sevick-Muraca E, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC. Challenges and key considerations of the enhanced permeability and retention effect (EPR) for nanomedicine drug delivery in oncology. Cancer Res 73: 2412–2417, 2013.
64. Seki T, Carroll F, Illingworth S, Green N, Cawood R, Bachtarzi H, Subr V, Fisher KD, Seymour LW. Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway. J Control Release 156: 381–389, 2011.
65. Seki T, Fang J, Maeda H. Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci 100: 2426–2430, 2009.
66. Seymour LW, Miyamoto Y, Maeda H, Brereton M, Strohalm J, Ulbrich K, Duncan R. Influence of molecular weight on passive tumour-accumulation of a soluble macromolecular drug-carrier. Eur J Cancer 31: 766–770, 1995.
67. Shibu ES, Hamada M, Murase N, Biju V. Nanomaterials formulations for photothermal and photodynamic therapy of cancer. J Photochem Photobiol C: Photochem Rev 15: 53–72, 2013.
68. Skinner SA, Tutton PJ, O'Brien PE. Microvascular architecture of experimental colon tumors in the rat. Cancer Res 50: 2411–2417, 1990.
69. Suzuki M, Hori K, Abe I, Saito S, Sato H. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst 67: 663–669, 1981.
70. Takeshita J, Maeda H, Kanamaru R. In vitro mode of action, pharmacokinetics, and organ specificity of poly (maleic acid-styrene)-conjugated neocarzinostatin, SMANCS. Gan 73: 278–284, 1982.
71. Torchilin V. Strategy and means for drug targeting: an overview. In: Biomedical Aspects of Drug Targeting, edited by Muzykantov VR, Torchilin VP. Norwell, MA: Kluwer Academic Publishers, 2002, p. 3–26.
72. Tsukigawa K, Liao L, Nakamura H, Fang J, Greish K, Otagiri M, Maeda H. Synthesis and therapeutic effect of styrene-maleic acid copolymer conjugated pirarubicin. Cancer Sci 106: 270–278, 2015.
73. Tsukigawa K, Nakamura H, Fang J, Otagiri M, Maeda H. Effect of different chemical bonds in pegylation of zinc protoporphyrin that affects drug release, intracellular uptake, and therapeutic effect in the tumor. Eur J Pharm Biopharm 89: 259–270, 2015.
74. Vicent MJ, Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol 24: 39–47, 2006.
75. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 339: 1546-1558, 2013.
76. Wang S, Fan W, Kim G, Hah HJ, Lee YE, Kopelman R, Ethirajan M, Gupta A, Goswami LN, Pera P, Morgan J, Pandey RK. Novel methods to incorporate photosensitizers into nanocarriers for cancer treatment by photodynamic therapy. Lasers Surg Med 43: 686–695, 2011.
77. Wu J, Akaike T, Hayashida K, Okamoto T, Okuyama A, Maeda H. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinase. Jpn J Cancer Res 92: 439–451, 2001.
78. Wu J, Akaike T, Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res 58: 159–165, 1998.
79. Yasuda H. Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide 19: 205–216, 2008.
80. Yasuda H, Yamaya M, Nakayama K, Sasaki T, Ebihara S, Kanda A, Asada M, Inoue D, Suzuki T, Okazaki T, Takahashi H, Yoshida M, Kaneta T, Ishizawa K, Yamanda S, Tomita N, Yamasaki M, Kikuchi A, Kubo H, Sasaki H. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 24: 688–694, 2006.
81. Yin H, Fang J, Liao L, Nakamura H, Maeda H. Styrene-maleic acid copolymer-encapsulated CORM2, a water-soluble carbon monoxide (CO) donor with a constant CO-releasing property, exhibits therapeutic potential for inflammatory bowel disease. J Control Release 187: 14–21, 2014.
82. Zhang R, Yang J, Sima M, Zhou Y, Kopeček J. Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates. Proc Natl Acad Sci USA 111: 12181–12186, 2014.